P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS

Detalles Bibliográficos
Autores principales: Delforge, Michel, Patel, Krina, Eliason, Laurie, Dhanda, Devender, Shi, Ling, Guo, Shien, Marshall, Thomas, Arnulf, Bertrand, Cavo, Michele, Nooka, Ajay, Manier, Salomon, Callander, Natalie, Giralt, Sergio, Einsele, Hermann, Ailawadhi, Sikander, Popa Mckiver, Mihaela, Cook, Mark, Rodríguez-Otero, Paula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430925/
http://dx.doi.org/10.1097/01.HS9.0000970524.03100.9e
_version_ 1785091076569169920
author Delforge, Michel
Patel, Krina
Eliason, Laurie
Dhanda, Devender
Shi, Ling
Guo, Shien
Marshall, Thomas
Arnulf, Bertrand
Cavo, Michele
Nooka, Ajay
Manier, Salomon
Callander, Natalie
Giralt, Sergio
Einsele, Hermann
Ailawadhi, Sikander
Popa Mckiver, Mihaela
Cook, Mark
Rodríguez-Otero, Paula
author_facet Delforge, Michel
Patel, Krina
Eliason, Laurie
Dhanda, Devender
Shi, Ling
Guo, Shien
Marshall, Thomas
Arnulf, Bertrand
Cavo, Michele
Nooka, Ajay
Manier, Salomon
Callander, Natalie
Giralt, Sergio
Einsele, Hermann
Ailawadhi, Sikander
Popa Mckiver, Mihaela
Cook, Mark
Rodríguez-Otero, Paula
author_sort Delforge, Michel
collection PubMed
description
format Online
Article
Text
id pubmed-10430925
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104309252023-08-17 P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS Delforge, Michel Patel, Krina Eliason, Laurie Dhanda, Devender Shi, Ling Guo, Shien Marshall, Thomas Arnulf, Bertrand Cavo, Michele Nooka, Ajay Manier, Salomon Callander, Natalie Giralt, Sergio Einsele, Hermann Ailawadhi, Sikander Popa Mckiver, Mihaela Cook, Mark Rodríguez-Otero, Paula Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430925/ http://dx.doi.org/10.1097/01.HS9.0000970524.03100.9e Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Posters
Delforge, Michel
Patel, Krina
Eliason, Laurie
Dhanda, Devender
Shi, Ling
Guo, Shien
Marshall, Thomas
Arnulf, Bertrand
Cavo, Michele
Nooka, Ajay
Manier, Salomon
Callander, Natalie
Giralt, Sergio
Einsele, Hermann
Ailawadhi, Sikander
Popa Mckiver, Mihaela
Cook, Mark
Rodríguez-Otero, Paula
P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS
title P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS
title_full P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS
title_fullStr P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS
title_full_unstemmed P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS
title_short P905: PATIENT REPORTED OUTCOMES IN TRIPLE CLASS EXPOSED, RELAPSED/REFRACTORY MULTIPLE MYELOMA (TCE RRMM) PATIENTS IN KARMMA 3 TRIAL (PHASE 3 RCT): IDECABTAGENE VICLEUCEL (IDE-CEL) VERSUS STANDARD REGIMENS
title_sort p905: patient reported outcomes in triple class exposed, relapsed/refractory multiple myeloma (tce rrmm) patients in karmma 3 trial (phase 3 rct): idecabtagene vicleucel (ide-cel) versus standard regimens
topic Posters
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430925/
http://dx.doi.org/10.1097/01.HS9.0000970524.03100.9e
work_keys_str_mv AT delforgemichel p905patientreportedoutcomesintripleclassexposedrelapsedrefractorymultiplemyelomatcerrmmpatientsinkarmma3trialphase3rctidecabtagenevicleucelidecelversusstandardregimens
AT patelkrina p905patientreportedoutcomesintripleclassexposedrelapsedrefractorymultiplemyelomatcerrmmpatientsinkarmma3trialphase3rctidecabtagenevicleucelidecelversusstandardregimens
AT eliasonlaurie p905patientreportedoutcomesintripleclassexposedrelapsedrefractorymultiplemyelomatcerrmmpatientsinkarmma3trialphase3rctidecabtagenevicleucelidecelversusstandardregimens
AT dhandadevender p905patientreportedoutcomesintripleclassexposedrelapsedrefractorymultiplemyelomatcerrmmpatientsinkarmma3trialphase3rctidecabtagenevicleucelidecelversusstandardregimens
AT shiling p905patientreportedoutcomesintripleclassexposedrelapsedrefractorymultiplemyelomatcerrmmpatientsinkarmma3trialphase3rctidecabtagenevicleucelidecelversusstandardregimens
AT guoshien p905patientreportedoutcomesintripleclassexposedrelapsedrefractorymultiplemyelomatcerrmmpatientsinkarmma3trialphase3rctidecabtagenevicleucelidecelversusstandardregimens
AT marshallthomas p905patientreportedoutcomesintripleclassexposedrelapsedrefractorymultiplemyelomatcerrmmpatientsinkarmma3trialphase3rctidecabtagenevicleucelidecelversusstandardregimens
AT arnulfbertrand p905patientreportedoutcomesintripleclassexposedrelapsedrefractorymultiplemyelomatcerrmmpatientsinkarmma3trialphase3rctidecabtagenevicleucelidecelversusstandardregimens
AT cavomichele p905patientreportedoutcomesintripleclassexposedrelapsedrefractorymultiplemyelomatcerrmmpatientsinkarmma3trialphase3rctidecabtagenevicleucelidecelversusstandardregimens
AT nookaajay p905patientreportedoutcomesintripleclassexposedrelapsedrefractorymultiplemyelomatcerrmmpatientsinkarmma3trialphase3rctidecabtagenevicleucelidecelversusstandardregimens
AT maniersalomon p905patientreportedoutcomesintripleclassexposedrelapsedrefractorymultiplemyelomatcerrmmpatientsinkarmma3trialphase3rctidecabtagenevicleucelidecelversusstandardregimens
AT callandernatalie p905patientreportedoutcomesintripleclassexposedrelapsedrefractorymultiplemyelomatcerrmmpatientsinkarmma3trialphase3rctidecabtagenevicleucelidecelversusstandardregimens
AT giraltsergio p905patientreportedoutcomesintripleclassexposedrelapsedrefractorymultiplemyelomatcerrmmpatientsinkarmma3trialphase3rctidecabtagenevicleucelidecelversusstandardregimens
AT einselehermann p905patientreportedoutcomesintripleclassexposedrelapsedrefractorymultiplemyelomatcerrmmpatientsinkarmma3trialphase3rctidecabtagenevicleucelidecelversusstandardregimens
AT ailawadhisikander p905patientreportedoutcomesintripleclassexposedrelapsedrefractorymultiplemyelomatcerrmmpatientsinkarmma3trialphase3rctidecabtagenevicleucelidecelversusstandardregimens
AT popamckivermihaela p905patientreportedoutcomesintripleclassexposedrelapsedrefractorymultiplemyelomatcerrmmpatientsinkarmma3trialphase3rctidecabtagenevicleucelidecelversusstandardregimens
AT cookmark p905patientreportedoutcomesintripleclassexposedrelapsedrefractorymultiplemyelomatcerrmmpatientsinkarmma3trialphase3rctidecabtagenevicleucelidecelversusstandardregimens
AT rodriguezoteropaula p905patientreportedoutcomesintripleclassexposedrelapsedrefractorymultiplemyelomatcerrmmpatientsinkarmma3trialphase3rctidecabtagenevicleucelidecelversusstandardregimens

Ejemplares similares